Andera Partners

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ayming is a management consulting firm headquartered in Levallois, France, that focuses on optimizing operational performance for its clients. The company provides a range of services, including consulting on human resources costs, tax strategies, operational costs optimization, software solutions, and energy and environmental issues. Additionally, Ayming offers advisory services related to work contributions and wage audits. By leveraging these diverse consulting offerings, Ayming aims to help organizations enhance their efficiency and overall performance while effectively managing social costs associated with taxes and financial operations.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Qovoltis operates in the renewable energy sector, focusing on innovative charging solutions for electric vehicles. The company offers a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. Additionally, Qovoltis provides a mobile application that enables users to authenticate and manage their charging remotely. The company caters not only to individual users but also to real estate projects by offering advanced charging station solutions that enhance asset value. Their services include the installation of delivery points, terminal connections, real-time terminal supervision, and the provision of electricity at competitive rates, allowing customers to effectively manage and optimize their charging experiences.

Skysun is a financial institution that provides financial solutions and services to the solar energy sector.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Mylight150 contributes to the creation of a society in which people generates own electricity to ensure self-sufficiency and long-term abundance.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Qualisteo, a start-up company based in Nice specialised in smart grids company.

Kepler Consulting is a provider of business management consulting services, serving a diverse range of industries including automotive, capital goods, aviation, consumer products, and more. The firm specializes in areas such as innovation, purchasing, supply chain management, marketing, sales, and operations. By focusing on these key areas, Kepler Consulting helps its clients improve efficiency and optimize operating margins, ultimately enhancing overall productivity and profitability. The company works with various industrial clients, including those in the public sector, luxury goods, retail, distribution, and services, as well as sectors like automotive and cosmetics.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

BioVentrix, Inc. is a medical device company based in San Ramon, California, focused on advancing treatments for congestive heart failure (CHF), particularly due to ischemic cardiomyopathy. The company has developed the Revivent Myocardial Anchoring System, a device designed to enhance cardiac function by restoring the size and volume of the left ventricle in affected patients. This innovative system employs a hybrid closed-chest transcatheter procedure that utilizes micro-anchoring pairs to separate scarred myocardium from healthy tissue, thereby improving overall heart performance. BioVentrix aims to provide less invasive, catheter-based approaches to manage the anatomical damage associated with CHF, thereby slowing the progression of this serious condition. Founded in 2003, the company was previously known as CHF Technologies, Inc.

Andera Partners, founded in 2001 and based in Paris, France, is a private equity firm that specializes in investing in growth-stage companies. The firm focuses on a diverse range of sectors, including sustainable energy, transportation and logistics, agribusiness, business-to-business and business-to-consumer services, building and construction, cosmetics, distribution, information technology and software, media, medical technology, real estate, therapeutic products, and tourism. Andera Partners employs a strategy centered on buyouts, aiming to support companies with innovative solutions and sustainable growth potential. With a commitment to fostering long-term performance, the firm leverages its expertise and experience to anticipate market trends and cultivate valuable relationships with its portfolio companies.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

SoniVie is engaged in the development of a medical device aimed at treating pulmonary hypertension through advanced denervation techniques. The company’s device involves a catheter that is inserted into the pulmonary artery during a minimally invasive procedure. This device selectively targets and damages the nerves linked to the disease without affecting the vessel walls or surrounding tissues, allowing physicians to effectively address the condition.

Senstronic is an automotive company that specializes in the design and manufacture of detection-based solutions and connectors for various applications, including automotive, aeronautics, and high-resistance environments like railways and agricultural machinery. The company's product range includes various types of sensors, such as inductive, magnetic, capacitive, and optic-electronic proximity sensors, as well as splitting systems. By addressing complex challenges faced by clients, Senstronic aims to enhance operational efficiency and increase return on investment for its customers.

Qovoltis operates in the renewable energy sector, focusing on innovative charging solutions for electric vehicles. The company offers a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. Additionally, Qovoltis provides a mobile application that enables users to authenticate and manage their charging remotely. The company caters not only to individual users but also to real estate projects by offering advanced charging station solutions that enhance asset value. Their services include the installation of delivery points, terminal connections, real-time terminal supervision, and the provision of electricity at competitive rates, allowing customers to effectively manage and optimize their charging experiences.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Resonance Imaging Group provides all patients with access to medical imaging, for increasingly precise diagnoses.

HR Path is a global consultancy focused on human resources, with a workforce of over 500 consultants operating in North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting. It offers human capital management technology and is an authorized reseller of various software solutions in France, including SAP, SuccessFactors, Oracle HCM, and others. Additionally, HR Path has developed proprietary HR software solutions such as BiHRdy, a business intelligence tool, Pandore, which integrates HR, payroll, and time management, and Geef, a talent management system. The company's diverse client portfolio includes several prominent companies listed on the CAC 40, as well as small and medium-sized enterprises and public sector organizations. HR Path is dedicated to supporting businesses throughout their digital transformation by enhancing human resource operations through innovative technology.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

ERI specializes in providing electrical and technical engineering services for both private and public project owners in the construction and industrial sectors. The company offers a comprehensive range of services, including the installation of high and low-voltage electrical equipment, technical cabling, and various telecom systems such as radio, video, and optical fibers. Additionally, ERI is involved in climate engineering activities and offers services related to construction, renovation, and routine maintenance. With expertise across all areas of the construction industry, ERI aims to meet the diverse needs of its clients effectively.

Kyotherm is an investment company that focuses on financing renewable heat production and energy efficiency projects. The company provides equity investment services to energy service providers, engineering firms, developers, heat consumers, and equipment manufacturers, assisting them in securing third-party financing for their initiatives. Kyotherm specializes in acquiring majority stakes in green energy generation projects, including geothermal and biomass heating plants, as well as district heating networks. By facilitating project capital, Kyotherm enables clients to develop diverse energy infrastructures while enhancing the contractual and financial structuring of these projects.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Lhyfe is a company based in Nantes, France, that specializes in the design, development, and operation of industrial sites for the production of green hydrogen using renewable energy sources such as wind and solar power. Founded in 2017, Lhyfe aims to provide substantial quantities of clean and affordable hydrogen, facilitating the transition of various industrial sectors and transportation towards a sustainable energy framework. The company focuses on two primary markets: heavy mobility, including trucks, buses, trains, and potentially maritime and air transport, as well as industrial applications, targeting industries such as chemistry, steel, and glass production. By integrating its production facilities with available renewable energy sources, Lhyfe ensures a minimal environmental footprint while addressing the urgent need to reduce greenhouse gas emissions.

ImmoCity provides real estate investment and management services for both individuals and institutions or private companies. Their services include asset management, compelling investment opportunities, investment discipline, alignment of interests, strategic and institutional risk management compliance, and enabling clients to access proper mediums for their investment and expansion.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing treatments for dementia and other neurological conditions. The company specializes in a targeted drug rescue program aimed at repurposing approved medications for new therapeutic indications. Exciva's approach includes the creation of symptomatic and disease-modifying therapies, alongside other formulations designed to address both neurological and psychological aspects of behavioral symptoms. By enabling the healthcare industry to access its innovative program, Exciva aims to improve treatment options and outcomes for patients suffering from various conditions, particularly those associated with dementia.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

MC2-Technologies specializes in the development of innovative equipment designed to protect sensitive sites and infrastructures. The company focuses on manufacturing advanced microwave amplifiers and employs expertise in microwave frequencies and nanotechnologies. Its offerings include the characterization, modeling, and design of microwave components and devices. By serving clients in the defense, security, and telecommunications sectors, MC2-Technologies enables effective protection solutions tailored to the needs of these industries.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Sogetrel, S.A.S. specializes in designing, deploying, and maintaining network infrastructures and digital communication solutions. Founded in 1985 and headquartered in Issy les Moulineaux, France, the company serves various sectors, including telecommunications, public authorities, defense, transport, and utilities. Sogetrel offers a range of services, such as the integration of communication systems, installation of telecommunication networks, and implementation of IP security measures like video surveillance and access control. Additionally, the company provides consultancy for smart city projects, along with supervision and image analysis services. With a focus on enhancing the quality of life for citizens and improving operational efficiency for businesses, Sogetrel has established itself as a key partner for major operators and local authorities, particularly in the deployment of high-speed networks. The company also has branches in Belgium and Switzerland, reinforcing its presence in the European market.

Sirsa, founded in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes, analyzing risks, and defining strategies to enhance operational sustainability. Sirsa provides a software-as-a-service platform for measuring companies' extra-financial footprint and impacts. It assists clients in implementing strategic initiatives, managing action plans, reporting results, and ensuring compliance with regulations. The firm serves a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental services, and software, among others.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

MasterGrid, based in Grenoble, France, specializes in the manufacture and supply of high voltage electrical equipment tailored for the commercial and industrial sectors. Established in 2019, the company produces a range of products including high, medium, and low-voltage equipment designed for the distribution, protection, control, and management of electrical systems. In addition to manufacturing, MasterGrid offers equipment handling services, ensuring that clients receive safe and durable products that enhance performance and efficiency.

Olaqin is a healthcare service provider based in Suresnes, France, specializing in value-added e-health solutions for health professionals. The company caters to various sectors within the healthcare industry, offering services such as centralized payment, securing electronic care sheets, updating vital cards, and safeguarding access to online medical records. Olaqin operates through a distribution network that supports health professionals indirectly, while also engaging directly with public hospitals and pharmacies through service contracts. This comprehensive approach ensures that clients receive essential facilities, including biometrics and management support, enhancing the efficiency and security of healthcare operations.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Ellisphere is a reference for decision-making information, supporting and securing the decision-making of company executives and decision-makers in France and internationally via the BIGnet network, by providing them with economic and financial information on their trading partners.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

99 Advisory is a banking and insurance sectors are facing radical changes in their environments.

Travelsoft is a company focused on developing software solutions for the travel industry. It offers a Software-as-a-Service platform called Orchestra, which enables tourism professionals to create, manage, distribute, and administer leisure travel packages. The platform facilitates the distribution of various travel components, including journey packages, hotels, and flights, allowing users to manage their offerings across multiple distribution channels effectively. Through its innovative tools, Travelsoft aims to enhance the operational efficiency and reach of travel professionals in the leisure sector.

SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.

SPHEREA specializes in the design and production of modular testing solutions for various electrical applications, catering to manufacturers, equipment suppliers, integrators, and rail operators. The company offers a range of products including model-based testing systems, field test equipment, wiring testers, and assisted maintenance and repair solutions. SPHEREA's expertise spans the entire life cycle of complex electronic, microwave, optronic, and mechatronic systems, serving critical sectors such as civil aeronautics, defense, energy, and rail both in France and internationally.

HR Path is a global consultancy focused on human resources, with a workforce of over 500 consultants operating in North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting. It offers human capital management technology and is an authorized reseller of various software solutions in France, including SAP, SuccessFactors, Oracle HCM, and others. Additionally, HR Path has developed proprietary HR software solutions such as BiHRdy, a business intelligence tool, Pandore, which integrates HR, payroll, and time management, and Geef, a talent management system. The company's diverse client portfolio includes several prominent companies listed on the CAC 40, as well as small and medium-sized enterprises and public sector organizations. HR Path is dedicated to supporting businesses throughout their digital transformation by enhancing human resource operations through innovative technology.

Tournus Equipement, S.A.S. is a manufacturer based in Tournus, France, specializing in stainless steel environments for professional kitchens and supermarket fish counters. The company provides a wide range of products, including mobile and modular kitchens, regeneration ovens, warmers, sterilizing cabinets, and various kitchen units. It also designs and manufactures equipment such as trolleys, containers, wash-basins, dishwashing equipment, and shelving products. Tournus Equipement serves diverse sectors, including canteens, restaurants, bakeries, supermarkets, and transport catering services. In addition to its manufacturing capabilities, the company offers joint design, installation, and express delivery services, catering to the specific needs of its clients. Founded in 1910, Tournus Equipement is known for its commitment to quality and durability in commercial kitchen solutions.

Verbraeken Infra builds and renovates utility infrastructure networks for gas, water, electricity and telecom companies. Vebraeken-Infra generates sales of € 140 million annually, with 1.000 employees across Belgium, France and Germany. Waterland supports Infra Group in its continued expansion in Europe and beyond. This growth strategy resulted in expansion of Verbraeken-Infra’s footprint both organically as well as through acquisitions in France, Germany and the Benelux and has strengthened Verbraeken-Infra’s leading market position in Belgium.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing treatments for dementia and other neurological conditions. The company specializes in a targeted drug rescue program aimed at repurposing approved medications for new therapeutic indications. Exciva's approach includes the creation of symptomatic and disease-modifying therapies, alongside other formulations designed to address both neurological and psychological aspects of behavioral symptoms. By enabling the healthcare industry to access its innovative program, Exciva aims to improve treatment options and outcomes for patients suffering from various conditions, particularly those associated with dementia.

Lease Protect has specialized in the fight against shrinkage by offering a range of products and services for video surveillance, security gates and customer counting. Under the leadership of its leaders, the offer focused specifically on the small and medium-sized business market thanks to local proximity, responsiveness enabled by the integration of the latest technologies connected to their equipment, and innovative financing solutions. Leasing products and services.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Solware Group is a software publisher that specializes in providing innovative and scalable solutions for the medico-social sector and the automotive industry. The company develops robust enterprise software tailored to meet the specific needs of medical facilities and auto garage owners. By focusing on the unique challenges faced by these sectors, Solware Group aims to enhance operational efficiency and address everyday professional issues for its clients. Through its commitment to evolving technology, the company supports users in navigating their daily business environments effectively.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

The Bioclinic Group is a medical company that operates medical analysis laboratories. It was founded in 1995 and is based in Paris, France.

Groupe JORYF is a specialist in housing construction located in Ile-de-France. The company provides a range of construction and engineering services tailored for the housing market. Its offerings include in-house structural work, masonry, and the development of various types of housing such as collective housing, single-family homes, and offices. Additionally, Groupe JORYF engages in the construction of tourist hotels, student housing, and residences for the elderly, demonstrating its versatility and commitment to meeting diverse housing needs.

Platinum Invest group specializes in jewelry production for luxury brands.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Skill & You is a prominent provider of vocational e-learning in France, focusing on delivering effective education and recognized qualifications such as BAC PRO, BEP, BP, BTS, and CAP. The company addresses the pressing issue of employment by offering a range of customized online courses that cater to the evolving needs of both learners and businesses. Its platform emphasizes adaptability and innovation, enabling users to acquire professional skills necessary for job adaptation, skill enhancement, and personal development. With a strong track record across various sectors, Skill & You empowers individuals to improve their lives through education, leveraging extensive expertise and a commitment to professionalism.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

orbility is a provider of off-street parking applications and programs.The company's parking assistance tools offers complete operational and management control of the car parking system being used. Its client base include airports, shopping centers, airports, municipalities, public and private operators.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

BIOGROUP-LCD, a major French player in local medical biology, supports more than 20,000 patients every day and offers more than 2000 routine and specialized daily examinations, based on performance and technological innovation. Partner at every moment between the patient and the medical profession, your laboratory participates in the screening, diagnosis, monitoring and prognosis of the most common pathologies to the most demanding, throughout your course of care. BIOGROUP-LCD develops for this purpose all its human and technological resources. The team of qualified, qualified medical biologists follows continuous and regular training.

The WALOR Group is a prominent European leader in the mechanical parts market, with 12 production sites across five countries and a workforce of 1,600 employees. The company specializes in the design, production, and assembly of high-precision mechanical parts and sub-systems, primarily through cold forging and machining processes. Its product offerings include forgings and machined components for critical applications such as engines, gearboxes, and steering systems. WALOR serves major manufacturers, system operators, and automotive suppliers, helping them meet their quality, cost, and capacity requirements in the automotive and energy sectors.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Created in 2016, TimeOne is a marketing services group formed from two online marketing specialists, Public-Idées and Place des Leads. The group’s core offering is to provide content and data solutions. With a well-established reputation in prescriptive marketing and a common technological base (DMP), TimeOne is founded on innovation and realized through research and development. TimeOne offers a comprehensive range of online marketing solutions: Programmatic, Native, Performance, digital Marketplace, Publishing and Mobile. The company has a presence in France, in the United-Kingdom, in Spain, Italy, South Africa, Asia and South America.

GLOBE Groupe is a Paris-based agency that specializes in advertising services and strategic marketing. The company offers a range of services including communication strategy, talent castings, recruitment, training, payroll, and various logistical solutions such as storage, dispatch, and cold-chain logistics. GLOBE focuses on shopper marketing, implementing experiences that convert consumers into shoppers while assessing campaign effectiveness through established performance indicators. They utilize a comprehensive methodology to evaluate the impact of their marketing efforts, ensuring that all operations are tracked through a secure extranet platform, myGLOBE, which provides real-time updates and data confidentiality. The company serves diverse sectors including consumer goods, media, and retail, aiming to enhance brands' commercial transformation and drive sales growth for its clients.

La Vie Saine includes the retail sale of specialized foods such as eggs, poultry, health foods, spices, herbs, coffee, and tea.

Groupe conseil en marketing client et communication, nativement inspiré par la data et les nouvelles technologies.

Allodiagnostic SAS, based in Paris, France, specializes in providing essential real estate diagnostics, including assessments for termites, electrical systems, and energy performance. Founded in 2001, the company caters to private individuals during the sale or rental of properties. It serves as a key resource for both consumers and real estate professionals, offering tailored solutions to meet various diagnostic requirements. As of July 2017, Allodiagnostic operates as a subsidiary of Edmond de Rothschild (France).

Intech is a leading manufacturer of orthopedic instruments and implants dedicated to enhancing patient outcomes. Operating with a workforce of around 1,000 employees globally, the company provides comprehensive manufacturing solutions to medical device original equipment manufacturers (OEMs). Intech specializes in a wide range of surgical tools, including implants, sterilization cases, and trays, catering to various medical fields such as spine, hip, knee, sports medicine, and trauma surgery. With facilities located in the United States, France, and Malaysia, Intech is positioned as a one-stop shop for medical device OEMs, delivering both off-the-shelf and custom-made instruments efficiently and cost-effectively.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Sarawak Group is a company specialized in setting up Sales-, Merchandising- and Brand Activation services. We seek to accelerate the performance and results of sales of products and services of our customers.

Studia as a reference in the fields of enterprise content management and document engineering in a complex environment.

Groupe 3S SAS, through its subsidiaries, provides ground handling for airlines and services to airport managers. The company offers ground handling services, including passenger, baggage handling, load control and dispatch, ramp activity, and crew handling services; and airport services, such as assistance to persons with disabilities or with reduced mobility, management of taxis areas, baggage trolleys, airports cleaning, aircraft de-icing, runway and areas cleanliness, safety, and others services. It also provides industrial cleaning, cleanliness, ultra-cleanliness, and facility management services, and home support services to individuals; and aviation security, dangerous goods, and ground handling training courses. The company was founded in 2001 and is based in Roissy-en-France, France. Groupe 3S SAS is a prior subsidiary of Latécoère S.A.